Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy, Annals of Oncology, May 2011, Oxford University Press (OUP),
DOI: 10.1093/annonc/mdr125.
You can read the full text:
Contributors
The following have contributed to this page
